Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Multiple Sclerosis.
Role of regulatory b cells in neuroimmunologic disorders.
Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Multiple sclerosis: association with HL-A3.
AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of masitinib in the treatment of pancreatic cancer
A map of the human neocortex showing the estimated overall myelin content of the individual architectonic areas based on the studies of Adolf Hopf.
Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.
Radiologically isolated syndrome: 5-year risk for an initial clinical event.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Information for healthcare professionals: Rituximab
Mitoxantrone: benefits and risks in multiple sclerosis patients.
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Copaxone
Comprehensive Immunophenotyping of CSF cells in relapsing-remitting multiple sclerosis patients with daclizumb therapy
Long-term effectiveness of glatiramer acetate in clinical practice conditions.
Extavia Prescribing Information
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence.
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

Pages